Spasticity at up to 6 hours after treatment (measured by the Ashworth Scale, 0‐, with a higher score indicating greater spasticity) · children/young people aged 4‐18 years with traumatic brain injury and with 'mild to severe spastic tetraparesis' (weakness) in all limbs
1 finding from 1 review
Adverse events · children/young people aged 4‐18 years with traumatic brain injury and with 'mild to severe spastic tetraparesis' (weakness) in all limbs
1 finding from 1 review
Sensory functions and pain · children/young people aged 4‐18 years with traumatic brain injury and with 'mild to severe spastic tetraparesis' (weakness) in all limbs
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Neuromusculoskeletal and movement‐related functions post treatment (measured by range of movement) · children/young people aged 4‐18 years with traumatic brain injury and with 'mild to severe spastic tetraparesis' (weakness) in all limbs
1 finding from 1 review
General tasks and demands · children/young people aged 4‐18 years with traumatic brain injury and with 'mild to severe spastic tetraparesis' (weakness) in all limbs
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mobility · children/young people aged 4‐18 years with traumatic brain injury and with 'mild to severe spastic tetraparesis' (weakness) in all limbs
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Self‐care · children/young people aged 4‐18 years with traumatic brain injury and with 'mild to severe spastic tetraparesis' (weakness) in all limbs
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Inadequate oxygenation (SaO₂ < 90% on peripheral oxygen saturation) · adult patients (18 years of age and older) for positive pressure ventilation undergoing elective surgery
It is very uncertain whether proSeal changes inadequate oxygenation (SaO₂ < 90% on peripheral oxygen saturation) compared with classic laryngeal mask airway (LMA) (very low certainty).
1 finding from 1 review
Inadequate ventilation ( ETCO₂ > 45 mm Hg) · adult patients (18 years of age and older) for positive pressure ventilation undergoing elective surgery
1 finding from 1 review
Time required for effective airway (seconds) · adult patients (18 years of age and older) for positive pressure ventilation undergoing elective surgery
1 finding from 1 review
Peak airway pressure during positive pressure ventilation (cm H₂O) · adult patients (18 years of age and older) for positive pressure ventilation undergoing elective surgery
1 finding from 1 review
Oropharyngeal leak pressure (seal pressure) (cm H₂O) · adult patients (18 years of age and older) for positive pressure ventilation undergoing elective surgery
1 finding from 1 review
Sore throat · adult patients (18 years of age and older) for positive pressure ventilation undergoing elective surgery
ProSeal showed no clear difference in sore throat compared with classic laryngeal mask airway (LMA) (low certainty).
1 finding from 1 review
Regurgitation · adult patients (18 years of age and older) for positive pressure ventilation undergoing elective surgery
ProSeal showed no clear difference in regurgitation compared with classic laryngeal mask airway (LMA) (low certainty).
1 finding from 1 review
Intervention not reported
Acute exacerbations (number of exacerbations/person/year) · adults (> 18 years of age) with either COPD or recurrent acute exacerbations of chronic bronchitis
The intervention showed no clear difference in acute exacerbations (number of exacerbations/person/year) (low certainty).
1 finding from 1 review
Intervention not reported
Mortality (deaths during trial period) · adults (> 18 years of age) with either COPD or recurrent acute exacerbations of chronic bronchitis
It is very uncertain whether the intervention changes mortality (deaths during trial period) (very low certainty).
1 finding from 1 review
Intervention not reported
Antibiotic prescriptions (number of courses/person/year) **Corticosteroids not meta‐analysed · adults (> 18 years of age) with either COPD or recurrent acute exacerbations of chronic bronchitis
The intervention may leads to higher antibiotic prescriptions (number of courses/person/year)… (low certainty).
1 finding from 1 review
Intervention not reported
Hospital admissions (number of participants hospitalised during trial period) · adults (> 18 years of age) with either COPD or recurrent acute exacerbations of chronic bronchitis
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Intervention not reported
Adverse events (number of adverse events/person/year) · adults (> 18 years of age) with either COPD or recurrent acute exacerbations of chronic bronchitis
The intervention showed no clear difference in adverse events (number of adverse events/person/year) (low certainty).
1 finding from 1 review
Intervention not reported
Quality of life Not meta‐analysed · adults (> 18 years of age) with either COPD or recurrent acute exacerbations of chronic bronchitis
1 finding from 1 review
no estimate extracted
Studies not reported
Very low